Additionally, activation of the PD-1/PD-L1 pathway not only impairs tumor immunity but also inhibits T cell migration and infiltration into the tumor site, further reducing the efficacy of CAR-T cells by limiting the presence of effective T cells within the TME. The gene discussed is PDCD1; the disease is neoplasm.